Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis [PDF]
, 2019 Background: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast
Block, Geoffrey A. +9 more
core +1 more source
Treatments for secondary hyperparathyroidism in hemodialysis [PDF]
Polish Archives of Internal Medicine, 2017 n ...
Piergiorgio Messa +2 more
openaire +3 more sources
PARATHYROID CANCER OCCURRING IN RELAPSING SECONDARY HYPERPARATHYROIDISM
Alʹmanah Kliničeskoj Mediciny, 2016 We present a clinical case of parathyroid cancer in a patient with relapsing secondary hyperparathyroidism at 4 years after subtotal parathyroidectomy.
I. V. Kotova +2 more
doaj +1 more source
Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review. [PDF]
, 2015 Background: Primary hyperparathyroidism (PHPT) is often found on routine blood tests, at a relatively asymptomatic stage. However many studies suggest different systemic effects related to PHPT, which could be enhanced by an abnormal cortisol release due
Armanini, Decio +6 more
core +2 more sources
Pakistan Armed Forces Medical Journal, 2020 Objective: To determine clinical decision limits (cut off points) for vitamin D deficiency based on secondary hyperparathyroidism. Study Design: Cross sectional study.
Afshan Bibi +5 more
doaj +2 more sources
Hyperparathyroidism: A rare cause of worsening of parkinsonism
Annals of Movement Disorders, 2020 Parkinsonism secondary to hypoparathyroidism is well described. The association of hyperparathyroidism with parkinsonism is rare. We describe here a case of progressive supranuclear palsy (PSP) associated with hyperparathyroidism secondary to a ...
Bhushan R Mishal +4 more
doaj +1 more source
Pathogenesis of refractory secondary hyperparathyroidism [PDF]
Kidney International, 2002 Calcitriol is currently used to reduce parathyroid hormone (PTH) levels in uremic patients. However, a significant number of patients fail to respond to calcitriol therapy. The data suggest that a poor response to calcitriol can be anticipated in patients with severe hyperparathyroidism (with a high basal PTH levels) and uncontrolled serum phosphate ...
Bartolome Garfia +9 more
openaire +3 more sources
Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche, 2021 Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). The progressive decline in renal function, in fact, leads to the alteration of the metabolism of calcium (Ca), phosphorus (P) and vitamin D.
Antonella Pino +5 more
doaj +1 more source
Efficacy of Ultrasound-guided Radiofrequency Ablation of Parathyroid Hyperplasia: Single Session vs. Two-Session for Effect on Hypocalcemia [PDF]
, 2020 To evaluate safety and efficacy of one- vs. two-session radiofrequency ablation (RFA) of parathyroid hyperplasia for patients with secondary hyperparathyroidism (SHPT) and to compare the outcome of both methods on hypocalcemia.
He, Hong-Feng +7 more
core +1 more source
Secondary hyperparathyroidism: recurrence after total parathyroidectomy with autotransplantation
Swiss Medical Weekly, 2019 BACKGROUND Secondary hyperparathyroidism is common in patients with end-stage chronic kidney disease. If drug therapy fails, total parathyroidectomy with autotransplantation of parathyroid tissue into the forearm (PTX-AT) is the most widely ...
Lukas Steffen +3 more
doaj +1 more source